Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Colorado, Boulder | OTHER |
Not provided
Not provided
Not provided
Not provided
This study will test whether 42 days of cannabis abstinence, compared to continued cannabis use, is associated with improvements in cognition and psychiatric disorder symptoms. Identical twins, who are concordant on cannabis use, will be experimentally-manipulated to be discordant for 42 days. Each twin, within a twin pair, will be randomly assigned to either the contingency management condition, incentive-based protocol to promote cannabis abstinence, or control condition, no changes in cannabis use requested.
The proposed project is a randomized controlled trial to compare cognition and psychiatric disorder symptoms between monozygotic (MZ) twin pairs, who are concordant on frequency of cannabis use. Each twin, within the twin pair, will be randomly assigned to either contingency management (CM), monetary incentives provided to reinforce cannabis abstinence, or control, no changes in cannabis use required or reinforced. Participants in the CM condition will receive an increasing schedule of payments at each visit reinforcing continued cannabis abstinence. All participants will receive increases in the payment schedule for attendance of each subsequent assessment. Participants will be assessed on measures of cognition including attention, memory, and processing speed as well as anxiety, depression, and ADHD symptoms. In addition, at each visit participants will complete a qualitative and quantitative drug test. The qualitative drug test will be used to determine if new cannabis use has occurred since the last visit, and will determine if the participant receives payment for abstinence. The investigators will also use previously collected genotype for each participant.
The first aim of this study is to characterize cognitive recovery, across all potential cognitive domains, using an experimental manipulation to achieve discordance between MZ twins on cannabis use. The hypothesis for the first aim is that the abstinent group will have greater improvements in memory and processing speed compared to controls. However, there will not be any group differences between the abstinent group and the control group on attention, language, and executive function performance. The second aim of the proposed project is to characterize psychiatric disorder symptoms by comparing psychiatric disorder symptom changes among the cannabis abstaining twin to their cannabis using co-twin across 42 days. The abstinent group will endorse more psychiatric symptoms during the withdrawal period (up to 14 days) but will endorse fewer psychiatric symptoms at day 28 and 42 compared to the control group. The third aim (exploratory) of the proposed project is to examine how genetic risk for psychiatric disorders interacts with environment (i.e., cannabis abstinence versus continued use) to influence cognitive functioning. The hypothesis for aim 3 is that anxiety, depression, and ADHD polygenic scores will be more strongly associated with cognitive outcomes in the control group compared to the abstinent group.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Contingency management | Experimental | Contingency management (CM) is an incentive-based intervention providing patients with tangible rewards as reinforcement for positive behaviors like abstinence from drug use. Incentives are provided with each urine sample that is drug-free and are increased with each subsequent drug-free urine sample. Participants in the CM condition will receive increasing payments for abstinence: $30 on day 3, $45 on day 5, $60 on day 7, $75 on day 14, $90 on day 21, $105 on day 28, and $120 on day 42. Participants in both conditions also receive increasing payment for visit attendance: $10 on day 1, $15 on day 3, $20 on day 5, $25 on day 7, $30 on day 14, $35 on day 21, $45 on day 28, and $55 on day 42. At the end of the baseline visit, participants in the CM condition will sign a behavioral contract with study staff that clearly outlines expectations as well as the payment schedule. |
|
| No intervention | No Intervention | Participants in this condition will be monitored and will not receive any compensation for cannabis abstinence. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Contingency management | Behavioral | Participants will be paid to abstain from cannabis use. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in attention performance | Flanker Inhibitory Control and Attention Test on NIH Toolbox: Composite score of accuracy and reaction time | Change from baseline to day 42 |
| Change in episodic memory | Picture Sequence Memory Test on NIH Toolbox: Cumulative number of correct adjacent pairs | Change from baseline to day 42 |
| Change in working memory | List Sorting Working Memory Test on NIH Toolbox: Total items correct across all trials | Change from baseline to day 42 |
| Change in receptive vocabulary | Picture Vocabulary Test on NIH Toolbox: Computer adaptive testing | Change from baseline to day 42 |
| Change in reading decoding | Oral Reading Recognition Test: Number of letters and words read correctly | Change from baseline to day 42 |
| Change in immediate memory/verbal learning | Auditory Verbal Learning Test on NIH Toolbox: Total number of words recalled | Change from baseline to day 4 |
| Change in pattern comparison processing speed | Pattern Comparison Processing Speed Test: Total number of correct responses | Change from baseline to day 42 |
| Change in oral symbol digit test processing speed |
| Measure | Description | Time Frame |
|---|---|---|
| Change in anxiety symptoms | Beck Anxiety Inventory: Total score. Scores range from 0-63 and higher scores indicate higher levels of anxiety. | Change from baseline to day 42 |
| Change in depressive symptoms |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1) Discordance in the twin pairs on a significant, adverse experience, like traumatic brain injury.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| J. Megan Ross, Ph.D. | University of Colorado, Denver | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Jessica M Ross | Aurora | Colorado | 80045 | United States |
In accordance with NIH data sharing policies, data produced from this project will be made available to ensure timely translation of research results to improve human health. The investigators believe there is a possibility of deductive disclosure of subjects with unusual characteristics, even though all identifiers would be removed prior to release for sharing. Thus, the investigators will make the data and associated documentation available to users only under a specific data-sharing agreement that requires: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002189 | Marijuana Abuse |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Oral Symbol Digit Test on NIH Toolbox: Total number of correctly identified symbols |
| Change from baseline to day 42 |
| Change in attention and executive function | Dimensional Change Card Sort Test on NIH Toolbox: Composite score of accuracy and correct answers | Change from baseline to day 42 |
Beck Depression Inventory: Total score. Scores range from 0-63 and higher scores indicate greater levels of depression.
| Change from baseline to day 42 |
| Change in attention deficit/hyperactivity disorder symptoms | Adult Self-Report Scale: Total score. Scores range from 0-72 and higher scores indicate greater level of symptoms of attention deficit/hyperactivity disorder. | Change from baseline to day 42 |